EICHORCondition: Desmoplastic Small Round Cell Tumor · Sponsor: Eli Lilly and Company
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital | Phoenix, Arizona, United States | — |
| Children's Hospital of Los Angeles | Los Angeles, California, United States | — |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | — |
| Washington University | St Louis, Missouri, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Children's Hospital of Philadelphia (CHOP) | Philadelphia, Pennsylvania, United States | — |
| Royal Children's Hospital | Parkville, Victoria, Australia | — |
| Universitaetsklinikum Freiburg | Freiburg im Breisgau, Baden-Wurttemberg, Germany | — |
| Universitaetsklinikum Essen | Essen, North Rhine-Westphalia, Germany | — |
| Universitaetsklinikum Hamburg-Eppendorf | Hamburg, Germany | — |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Lombardy, Italy | — |
| Humanitas | Rozzano, Milano, Italy | — |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04145349